- Previous Close
16.84 - Open
16.91 - Bid 11.67 x 200
- Ask 21.63 x 200
- Day's Range
16.91 - 16.91 - 52 Week Range
11.87 - 29.79 - Volume
3,467 - Avg. Volume
306,906 - Market Cap (intraday)
434.34M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-2.89 - Earnings Date May 12, 2025 - May 16, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
56.44
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.
www.tourmalinebio.comRecent News: TRML
View More
Performance Overview: TRML
Trailing total returns as of 3/27/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TRML
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TRML
View MoreValuation Measures
Market Cap
432.54M
Enterprise Value
174.48M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.44
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-21.60%
Return on Equity (ttm)
-28.99%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-73.21M
Diluted EPS (ttm)
-2.89
Balance Sheet and Cash Flow
Total Cash (mrq)
258.3M
Total Debt/Equity (mrq)
0.08%
Levered Free Cash Flow (ttm)
-50.17M
Research Analysis: TRML
View MoreCompany Insights: TRML
TRML does not have Company Insights
Research Reports: TRML
View MoreDaily – Vickers Top Insider Picks for 12/26/2023
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 12/22/2023
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 12/21/2023
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 11/29/2023
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.